DSGN — Design Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1807120 ·
Last close
$9.84
Market Cap
$630.12M
52W High
$17.25
52W Low
$7.25
ADV30
422,203
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -22,230,000 | -20,288,000 | 216,808,000 | 15,252,000 | 14,612,000 |
| Jun 2026 | 0 | — | -22,177,000 | -20,165,000 | 215,129,000 | 12,907,000 | 13,271,000 |
| Mar 2026 | 0 | — | -19,706,000 | -17,636,000 | 230,442,000 | 12,770,000 | 12,388,000 |
| Dec 2025 | 0 | — | -18,169,000 | -15,997,000 | 226,203,000 | 16,856,000 | 13,700,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,299,000
Investing CF
$-3,927,000
Financing CF
$63,390,000
CapEx
$-208,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.20
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-355,095,000
Inventory
—
Receivables
$1,743,000
ST Investments
$193,356,000
EBIT TTM
$-82,282,000
Pretax Income TTM
$-74,086,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -79,467,000 | -69,792,000 | 226,203,000 | 13,700,000 | 212,503,000 | -54,358,000 |
| Dec 2024 | 0 | -62,383,000 | -49,588,000 | 252,093,000 | 9,996,000 | 242,097,000 | -43,105,000 |
| Dec 2023 | 0 | -78,190,000 | -66,862,000 | 289,643,000 | 11,956,000 | 277,687,000 | -58,560,000 |
| Dec 2022 | 0 | -67,593,000 | -63,308,000 | 341,137,000 | 13,827,000 | 327,310,000 | -51,317,000 |
TTM Snapshot
Revenues TTM
$8,568,000
NetIncome TTM
$-70,795,000
OpCashFlow TTM
—
Assets (Latest)
$215,129,000
Forward EPS
$-1.62
Max Pain — expiry 2026-12-18
max pain strike: $10.00 · spot: $9.47 · call oi: 20,394 · put oi: 27
Expected Move to 2026-12-18:
±$2.95
(31.15%) —
implied range
$6.52 –
$12.42
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALMS | ALUMIS INC. | $628.33M | $4.84 | — |
| OLMA | Olema Oncology, Inc. | $632.52M | $7.22 | — |
| BCAX | Bicara Therapeutics Inc. | $637.32M | $9.60 | — |
| ABUS | Arbutus Biopharma Corp | $620.84M | $4.05 | — |
| SVA | SINOVAC BIOTECH LTD | $642.44M | $6.47 | — |
News headlines (Yahoo Finance, 1h cache)
Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
2026-11-04 21:01 · Yahoo
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
2026-05-18 11:00 · Yahoo
Design Therapeutics Inc (DSGN) Q1 2026 Earnings Call Highlights: Promising Progress in ...
2026-04-29 23:00 · Yahoo
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
2026-05-11 16:00 · Yahoo
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
2026-05-17 20:00 · Yahoo
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
2026-05-28 12:00 · Yahoo
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
2026-04-28 20:01 · Yahoo
Design Therapeutics Q1 Earnings Call Highlights
2026-04-29 09:04 · Yahoo
Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)
2026-05-18 14:02 · Yahoo
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch
2026-08-27 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.